Finer Market Points: ASX Top 10 Momentum Stocks: 31 Jan 2025TSX:ATH ASX:3DP NASDAQ:BXN NASDAQ:OPT ASX:ERM NYSE:PAR GETTEX:VTX LSE:GCM NYSE:EBR ASX:ESR Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first ap
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.045 AUD
−58.65 M AUD
65.80 K AUD
342.13 M
About PARADIGM BIOPHARMACEUTICALS LIMITED..
Sector
Industry
CEO
Paul John Rennie
Website
Headquarters
Melbourne
Founded
2014
ISIN
AU000000PAR5
FIGI
BBG009QNWX30
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
ASX: PAR - A possible 3rd wave upI'm seeing a possible 3rd wave move up, it seems to of completed a larger ABC corrective structure with a 1-2 wave from the C low.
I have set an early entry at 3.13, i want to see a sharp move up for evidence of a 3rd wave. If we do not get a sharp price move up the i will review this entry.
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves
1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20
-Being the end of the trading week I suspect the latter.
2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket'
-Bounce off st
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of PAR is 0.290 AUD — it has decreased by −7.94% in the past 24 hours. Watch PARADIGM BIOPHARMACEUTICALS LIMITED.. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange PARADIGM BIOPHARMACEUTICALS LIMITED.. stocks are traded under the ticker PAR.
PAR stock has fallen by −12.12% compared to the previous week, the month change is a −31.76% fall, over the last year PARADIGM BIOPHARMACEUTICALS LIMITED.. has showed a −1.69% decrease.
We've gathered analysts' opinions on PARADIGM BIOPHARMACEUTICALS LIMITED.. future price: according to them, PAR price has a max estimate of 2.07 AUD and a min estimate of 0.80 AUD. Watch PAR chart and read a more detailed PARADIGM BIOPHARMACEUTICALS LIMITED.. stock forecast: see what analysts think of PARADIGM BIOPHARMACEUTICALS LIMITED.. and suggest that you do with its stocks.
PAR stock is 10.34% volatile and has beta coefficient of 3.29. Track PARADIGM BIOPHARMACEUTICALS LIMITED.. stock price on the chart and check out the list of the most volatile stocks — is PARADIGM BIOPHARMACEUTICALS LIMITED.. there?
Today PARADIGM BIOPHARMACEUTICALS LIMITED.. has the market capitalization of 112.93 M, it has increased by 10.34% over the last week.
Yes, you can track PARADIGM BIOPHARMACEUTICALS LIMITED.. financials in yearly and quarterly reports right on TradingView.
PARADIGM BIOPHARMACEUTICALS LIMITED.. is going to release the next earnings report on Aug 29, 2025. Keep track of upcoming events with our Earnings Calendar.
PAR net income for the last half-year is −5.92 M AUD, while the previous report showed −9.69 M AUD of net income which accounts for 38.89% change. Track more PARADIGM BIOPHARMACEUTICALS LIMITED.. financial stats to get the full picture.
No, PAR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PARADIGM BIOPHARMACEUTICALS LIMITED.. EBITDA is −20.64 M AUD, and current EBITDA margin is −97.79 K%. See more stats in PARADIGM BIOPHARMACEUTICALS LIMITED.. financial statements.
Like other stocks, PAR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PARADIGM BIOPHARMACEUTICALS LIMITED.. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PARADIGM BIOPHARMACEUTICALS LIMITED.. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PARADIGM BIOPHARMACEUTICALS LIMITED.. stock shows the sell signal. See more of PARADIGM BIOPHARMACEUTICALS LIMITED.. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.